14.03.2024 • NewsTrinseoAmericas StyrenicsChevron Phillips

Trinseo to Sell Its Share in Americas Styrenics

US specialty materials producer Trinseo has commenced a sale process for its 50% ownership in Americas Styrenics (AmSty), a joint venture (JV) with Chevron Phillips Chemical.

As part of Trinseo’s transformation strategy, the company had previously announced its intent to divest its styrenics businesses with a focus on selectively marketing individual assets or regional businesses. AmSty was established in 2008 and is part of Trinseo’s regional Styrenics businesses operating in the Americas.

Trinseo has initiated an ownership exit provision of the AmSty JV agreement which includes a structured mechanism that is expected to ultimately lead to a sale of Trinseo’s ownership interest in AmSty. Any proceeds from the sale are expected to be used to pay down a portion of the recently issued $1.077 billion of term loans maturing in 2028.

Frank Bozich, president and CEO of Trinseo, said: “The sale of our ownership in AmSty is a logical step in our transformation as a specialty materials and sustainable solutions provider. By executing the contractual ownership exit provision, we have a clear pathway to divest our interest in the joint venture. We expect the exit process to lead to a definitive arrangement no later than early 2025.”

© MilsiArt/Shutterstock
© MilsiArt/Shutterstock

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.